Immunocore PLC - IMCR Net earnings per share for the last four quarters

The success of Immunocore Holdings plc (IMCR) is based on the global sales of Kimmtrak for ocular melanoma. This YoY ttm EPS chart clearly demonstrates market expectations, where the value of 0.00 expresses the metric level. Growth is driven by unique TCR technologies and interest from pharma behemoths. The company's strategy relies on the expansion of its innovative platform to combat solid tumors.
IMCR (Immunocore): analytical breakdowns and indicator data

To minimize investment risks, it is necessary to assess the stability of profit generation by filtering revenue volatility. This indicator measures the percentage change in net income per share over the trailing twelve months (TTM) relative to the previous year, while the history of the net income per share YoY TTM growth rate reflects the commercial success of Kimmtrak and the effectiveness of new clinical phases at Immunocore Holdings plc (IMCR).